- Home
- ELVN vs AMPH Comparison
ELVN vs AMPH Comparison
Compare ELVN & AMPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ELVN
- AMPH
- Stock Information
- Founded
- ELVN 2016
- AMPH 1996
- Country
- ELVN United States
- AMPH United States
- Employees
- ELVN N/A
- AMPH N/A
- Industry
- ELVN Biotechnology: Pharmaceutical Preparations
- AMPH Biotechnology: Pharmaceutical Preparations
- Sector
- ELVN Health Care
- AMPH Health Care
- Exchange
- ELVN Nasdaq
- AMPH Nasdaq
- Market Cap
- ELVN 927.8M
- AMPH 1.1B
- IPO Year
- ELVN 2020
- AMPH 2014
- Fundamental
- Price
- ELVN $18.42
- AMPH $24.11
- Analyst Decision
- ELVN Strong Buy
- AMPH Buy
- Analyst Count
- ELVN 4
- AMPH 4
- Target Price
- ELVN $39.25
- AMPH $40.67
- AVG Volume (30 Days)
- ELVN 260.6K
- AMPH 550.8K
- Earning Date
- ELVN 05-13-2025
- AMPH 05-07-2025
- Dividend Yield
- ELVN N/A
- AMPH N/A
- EPS Growth
- ELVN N/A
- AMPH N/A
- EPS
- ELVN N/A
- AMPH 2.77
- Revenue
- ELVN N/A
- AMPH $730,659,000.00
- Revenue This Year
- ELVN N/A
- AMPH $2.32
- Revenue Next Year
- ELVN N/A
- AMPH $6.60
- P/E Ratio
- ELVN N/A
- AMPH $8.54
- Revenue Growth
- ELVN N/A
- AMPH 8.05
- 52 Week Low
- ELVN $13.30
- AMPH $22.64
- 52 Week High
- ELVN $30.03
- AMPH $53.96
- Technical
- Relative Strength Index (RSI)
- ELVN 47.86
- AMPH 43.88
- Support Level
- ELVN $17.76
- AMPH $23.69
- Resistance Level
- ELVN $20.79
- AMPH $25.36
- Average True Range (ATR)
- ELVN 1.37
- AMPH 0.90
- MACD
- ELVN 0.12
- AMPH 0.22
- Stochastic Oscillator
- ELVN 45.39
- AMPH 42.73
About ELVN Enliven Therapeutics Inc.
Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. Its product candidates include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.
About AMPH Amphastar Pharmaceuticals Inc.
Amphastar Pharmaceuticals Inc is a bio-pharmaceutical company focusing on developing, manufacturing, marketing, and selling technically challenging generic and proprietary injectable, inhalation, and intranasal products, as well as insulin active pharmaceutical ingredient, or insulin API products. The company's finished products are used in hospital or urgent care clinical settings and are contracted and distributed through group purchasing organizations and drug wholesalers. The company has one reportable segment pharmaceutical products. Geographically the business presence of the firm is seen in the United States, China and France of which the U.S. accounts for the majority of the revenue.